Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.

MLA

Toorop, Alyssa A., et al. “Decrease of Natalizumab Drug Levels after Switching from Intravenous to Subcutaneous Administration in Patients with Multiple Sclerosis.” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 94, no. 6, June 2023, pp. 482–86. EBSCOhost, https://doi.org/10.1136/jnnp-2022-330467.

APA

Toorop, A. A., van Kempen, Z. L. E., Steenhuis, M., Nielsen, J., Sinnige, L. G. F., van Dijk, G., Roosendaal, C. M., Arnoldus, E. P. J., Hoitsma, E., Lissenberg-Witte, B. I., de Jong, B. A., Oosten, B. W. van, Strijbis, E. M. M., Uitdehaag, B. M. J., Rispens, T., & Killestein, J. (2023). Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 94(6), 482–486. https://doi.org/10.1136/jnnp-2022-330467

Chicago

Toorop, Alyssa A, Zoé L E van Kempen, Maurice Steenhuis, Jessica Nielsen, L G F Sinnige, Gert van Dijk, Christiaan M Roosendaal, et al. 2023. “Decrease of Natalizumab Drug Levels after Switching from Intravenous to Subcutaneous Administration in Patients with Multiple Sclerosis.” Journal of Neurology, Neurosurgery, and Psychiatry 94 (6): 482–86. doi:10.1136/jnnp-2022-330467.